<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954352</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0297</org_study_id>
    <nct_id>NCT04954352</nct_id>
  </id_info>
  <brief_title>Human Epidemiology of Newly Identified Arboviruses</brief_title>
  <acronym>ARBODOCC</acronym>
  <official_title>Epidemiology in Humans of New Arbovirusus Sorted Out From Metagenomic Screen in Local Vectors and Animal Hosts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMR ASTRE (CIRAD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMR PCCEI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A local network is being set up to study the impact of arboviruses in our region. It is&#xD;
      committed to a one-health approach, in particular with research without a priori for new&#xD;
      viruses hosted among vectors and wildlife. The candidates identified by high throughput&#xD;
      sequencing approaches will serve as a basis for the development of serological and molecular&#xD;
      tools for their detections. These tools will be used to assess the possible circulation of&#xD;
      these new viruses in humans in biological collections created within the framework of this&#xD;
      project Arbodocc&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence</measure>
    <time_frame>1 day</time_frame>
    <description>Detection of antibodies targeting specific antigens of newly identified arboviruses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular detection</measure>
    <time_frame>1 day</time_frame>
    <description>Detection of newly identified arboviruses genome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Arbovirus Infections</condition>
  <condition>SARS-CoV Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and CSF samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients admitted at the Monpellier University Hospital for any infectious syndrome&#xD;
             compatible with an arboviral infection&#xD;
&#xD;
          -  Healthy volunteers for seroprevalence investigation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Patients admitted at the Monpellier University Hospital for any infectious syndrome&#xD;
        compatible with an arboviral infection with samples available&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Informed consent non obtain for samples used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Foulongne, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick Simonin, PhD</last_name>
    <phone>434359114</phone>
    <phone_ext>33</phone_ext>
    <email>yannick.simonin@umontpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Foulongne, PhD</last_name>
    <phone>467 330 254</phone>
    <phone_ext>33</phone_ext>
    <email>v-foulongne@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Foulongne, PHD</last_name>
      <phone>467 330 254</phone>
      <phone_ext>33</phone_ext>
      <email>v-foulongne@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>SÃ©rafin Guttierez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Eloit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Simonin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with arboviral infection compatible signs</keyword>
  <keyword>Unexplained isolated fever</keyword>
  <keyword>Neurological infection conditions without any identified etiology</keyword>
  <keyword>Arbovirus</keyword>
  <keyword>Arboviral like infectious disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Arbovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

